CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Frequency, phenotype, outcome and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients
DOI 10.1055/s-0031-1285210
Bibliografische Angaben
Nachweis in CareLit
Autor:innenDC Baumgart, U Grittner, A Steingräber, M Azzaro, S Philipp
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2011
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: The monoclonal anti-tumor necrosis factor (TNF) antibody adalimumab has recently been approved for Crohn's disease (CD) and evaluated for ulcerative colitis (UC). Cutaneous lesions associated with its administration have not been prospectively studied in inflammatory bowel disease (IBD). Methods: We evaluated the first fifty consecutive patients (female n=30, median age 32½ years [IQR 27–46]) with CD (n=…
Zitieren
Zitierempfehlung
DC Baumgart, U Grittner, A Steingräber, M Azzaro, S Philipp (2011) Frequency, phenotype, outcome and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0031-1285210
Mit CareLit weiterarbeiten